The SURMOUNT-5 trial has provided definitive evidence that tirzepatide is superior to semaglutide for obesity treatment, achieving an additional 6.5% body weight reduction and nearly doubling the proportion of patients who lose 25% or more of their body weight.

This landmark head-to-head comparison, recently presented at the European Congress of Obesity in Spain, represents the first direct evidence comparing these two leading obesity medications helping to guide optimal treatment selection.